The content on this site is intended for healthcare professionals only
Co-Chair of the FLIMS Alumni session on advanced breast cancer at the 8th European Breast Cancer Conference, Dr Hutka discusses the benefits of the FLIMS workshop and her talk on the management of triple negative breast cancer, including hormonal treatment and HER2+ breast cancer.
Dr Hutka's work also focuses on gastrointestinal research.
CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
OncoAlert round up July 28th to August 3rd, 2023
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC
ASCO 2023: Breast cancer research highlights
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
